公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2021 | Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial | CHIH-HSIN YANG ; Mok T.S.K.; Lu S.; Nakagawa K.; Yamamoto N.; Shi Y.-K.; Zhang L.; Soo R.A.; Morita S.; Tamura T. | JTO Clinical and Research Reports | 0 | 0 | |
2022 | Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study | Kang Y.-K.; Morita S.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Chen L.-T.; Boku N. | Gastric Cancer | 7 | 7 | |
2018 | Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study | Kudo M.; ANN-LII CHENG ; Park J.-W.; Park J.H.; PO-CHIN LIANG ; Hidaka H.; Izumi N.; Heo J.; Lee Y.J.; Sheen I.-S.; Chiu C.-F.; Arioka H.; Morita S.; Arai Y. | The Lancet Gastroenterology and Hepatology | 126 | 114 | |
2020 | A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies | Yamamoto N.; Ryoo B.-Y.; Keam B.; Kudo M.; CHIA-CHI LIN ; Kunieda F.; Ball H.A.; Moran D.; Komatsu K.; Takeda K.; Fukuda M.; Furuse J.; Morita S.; Doi T. | Investigational New Drugs | 15 | 14 |